- Page 1 and 2:
Efficacy of pharmacological interve
- Page 3 and 4:
2.2.7 Clinical Course of IPF.......
- Page 5 and 6:
CHAPTER I: INTRODUCTION Idiopathic
- Page 7 and 8:
Progression-Free Survival (PFS) in
- Page 9 and 10:
is used (Azuma et al., 2005). The p
- Page 11 and 12:
Source: Adopted from Myllärniemi a
- Page 13 and 14:
disease is increased; however, no s
- Page 15 and 16:
CHAPTER II: LITERATURE REVIEW 2.1 I
- Page 17 and 18:
The dangerous disease basically att
- Page 19 and 20:
made between the inflammatory and f
- Page 21 and 22:
(Giotopoulos et al., 2007). RT of t
- Page 23 and 24:
derived cytokines, IL-5 and IL-9, m
- Page 25 and 26:
granulomatous lung disease, hence i
- Page 27 and 28:
infection and IPF (Wangoo et al., 1
- Page 29 and 30:
2.2.6 Pathophysiology Though the pa
- Page 31 and 32:
smoking (Rosas et al., 2007; Steele
- Page 33 and 34:
histological pattern of UIP in the
- Page 35 and 36:
The aim of this procedure is to rec
- Page 37 and 38:
procedures involving internal valid
- Page 39 and 40:
adiological diagnosis of HRCT (Ragh
- Page 41 and 42:
2.2.11.1 Clinical Predictors Age: A
- Page 43 and 44:
© 2017-2018 All Rights Reserved, N
- Page 45 and 46:
studies and have exhibited that inc
- Page 47 and 48:
Numerous physiologic parameters lik
- Page 49 and 50:
Dense fibrosis and honeycombing is
- Page 51 and 52:
Pharmacological treatment: Glucocor
- Page 53 and 54:
i. Oxygen Therapy and ventilation I
- Page 55 and 56:
Numerous patients with IPF acquirin
- Page 57 and 58:
should be undergone to reveal wheth
- Page 59 and 60:
CHAPTER III: RESEARCH METHODOLOGY T
- Page 61 and 62:
3.2 Meta-analysis of Randomised Con
- Page 63 and 64:
3.4.1 Inclusion criteria The inclus
- Page 65 and 66:
3.6.1 Dichotomous Comparisons The v
- Page 67 and 68:
CHAPTER IV: RESULTS 4.1 Introductio
- Page 69 and 70:
Following are the questions of the
- Page 71:
Study number Table 2- CASP assessme
- Page 75:
primary objective is to examined wh
- Page 79: to NAC inhaled inhaled NAC and oral
- Page 82: S. no Author; Year 1 Behr et al 7 C
- Page 86: pirfenidone combined with highdose
- Page 90: or temporary cessation of pirfenido
- Page 93: 4.5 Patient characteristics, interv
- Page 97: oom air 3 Sakamoto et al 15 Effecti
- Page 101 and 102: Of the studies considered for the s
- Page 103: 4.6 Evaluation of Efficacy of Prife
- Page 107: change in the lowest SPO2 during th
- Page 111: PaO2, and SaO2; episodes of AE-IPF
- Page 115 and 116: The efficacy of using NAC in combin
- Page 117 and 118: group. It is revealed that at the 2
- Page 119 and 120: CHAPTER V: DISCUSSION AND CONCLUSIO
- Page 121 and 122: contradicting results 50 51 . A res
- Page 123 and 124: tolerability and safety of pirfenid
- Page 125 and 126: equired. An exploratory efficacy an
- Page 127: as to verify the results and acquir
- Page 131 and 132: American Thoracic Society. Idiopath
- Page 133 and 134: and clinical immunology. 115 (1). p
- Page 135 and 136: Behr, J., Maier, K., Degenkolb, B.,
- Page 137 and 138: Bowling, A. (2009). Research Method
- Page 139 and 140: 878-81. Available from: http://www.
- Page 141 and 142: http://www.ncbi.nlm.nih.gov/pubmed/
- Page 143 and 144: El-Chemaly, S., Ziegler, S.G., Cala
- Page 145 and 146: Flaherty, K.R., Andrei, A.-C., Murr
- Page 147 and 148: pirfenidone on the generation of re
- Page 149 and 150: Hansell, D.M., Bankier, A.A., MacMa
- Page 151 and 152: proteoglycan deposition in the airw
- Page 153 and 154: Nishimura, J. & Inoue, T. (2009). A
- Page 155 and 156: 313-9. Available from: http://www.n
- Page 157 and 158: Pereira, C.A., Sahn, S.A., Sussman,
- Page 159 and 160: interstitial pneumonia: the prognos
- Page 161 and 162: Leslie, K.O., Gruden, J.F., Parish,
- Page 163 and 164: America. 25 (4). pp. 709-721. Marti
- Page 165 and 166: Meyer, A., Buhl, R. & Magnussen, H.
- Page 167 and 168: Moseley, P.L., Hemken, C. & Hunning
- Page 169 and 170: topics/topics/idiopathic-pulmonary-
- Page 171 and 172: Olson, A.L., Swigris, J.J., Lezotte
- Page 173 and 174: Piguet, P.F., Vesin, C., Grau, G.E.
- Page 175 and 176: open-label Phase II study. American
- Page 177 and 178: Rødningen, O.K., Børresen-Dale, A
- Page 179 and 180:
Experimental Biology and Medicine.
- Page 181 and 182:
Silva, C.I.S., Müller, N.L., Fujim
- Page 183 and 184:
Sutton, A.J. (2000). Methods for me
- Page 185 and 186:
(11). pp. 1085-1094. Tomioka, H., K
- Page 187 and 188:
Wang, Q., Zhu, H., Zhou, W.-G., Guo
- Page 189 and 190:
http://www.nature.com/doifinder/10.
- Page 191 and 192:
silica-induced lung fibrosis in the